Amarin Corp Plc (AMRN)

[biowreck]

Read the label "it is not known if Vascepa prevents you from having a heart attack or stroke". I understand this to be a major issue for the FDA, and that is the approval of CV drugs that aren't not known to reduce CV events and they want to change this. However, I don't believe that this change in position on the FDA's part should grandfather in drugs that are already approved or in trials such as anchor where millions $ have been spent and patients have seen improvements in lipid panels. Anchor should never been rescinded, it was a poor decision on the FDA's part, and as a result a lot of trust and confidence has been lost on the FDA by the American public.